Walgreens Boots Alliance, Inc. (Nasdaq: WBA) has announced the appointment of William H. Shrank, M.D. to the company’s board of directors. Dr. Shrank brings with him extensive healthcare experience, business leadership, and clinical expertise. He is a venture partner with the Bio + Health Team of Andreesen Horowitz, a private venture capital firm, and has previously held senior leadership roles with Fortune 50 companies, including Chief Medical Officer for Humana, Inc. and Chief Scientific Officer and CMO of Provider Innovation for CVS Health.
WBA has been strengthening its leadership team with several new executive appointments earlier this year to deepen the company’s healthcare expertise and position the company for accelerated growth.
Walgreens Boots Alliance (Nasdaq: WBA) is an integrated healthcare, pharmacy, and retail leader serving millions of customers and patients every day, with approximately 12,500 locations across the U.S., Europe, and Latin America. The company employs more than 330,000 people and has a presence in eight countries through its portfolio of consumer brands, including Walgreens, Boots, Duane Reade, the No7 Beauty Company, and Benavides in Mexico.
WBA has been recognized for its commitment to operating sustainably and has been named to the 100 Best Corporate Citizens 2022. The company is an index component of the Dow Jones Sustainability Indices (DJSI).
Today the company's shares have moved 4.4% to a price of $11.26. For the full picture, make sure to review Walgreens Boots Alliance's 8-K report.
